Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

certolizumab pegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
TNF-α/NF-κB/Snail pathway in cancer cell migration and invasion
Tumour necrosis factor-alpha (TNF-α) is an important inflammatory factor that acts as a master switch in establishing an… Expand
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
BACKGROUND Inhibitors of tumor necrosis factor alpha (TNFalpha) have demonstrated significant efficacy in chronic inflammatory… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 7
Is this relevant?
Review
2007
Review
2007
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's… Expand
Is this relevant?
2007
2007
Treatment of Crohn's disease with certolizumab pegol.
Biologic therapies have revolutionized the treatment of Crohn's disease (CD). Targeting TNF-alpha with monoclonal antibodies has… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… Expand
Is this relevant?
2005
2005
In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870): 807
 
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
BACKGROUND CDP870 is a PEGylated Fab' fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor-alpha… Expand
Is this relevant?
2004
2004
Pharmaceutical profiling in drug discovery for lead selection
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… Expand
  • table 1.1
  • figure 1.1
  • figure 1.2
  • figure 1.3
  • figure 2.1
Is this relevant?
Review
2003
Review
2003
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
The introduction of infliximab, a mouse/human chimeric monoclonal antibody to tumor necrosis factor (TNF), is an important… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE